Navigation Links
Nile Therapeutics Announces Positive Phase 1a Results of CD-NP, a Selective NPR-B Agonist in Clinical Development for the Treatment of Heart Failure
Date:10/11/2007

BERKELEY, Calif., Oct. 11 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (OTC Bulletin Board: SPDU), today announced results from a Phase 1a clinical study of CD-NP, Nile's selective NPR-B agonist being developed for the treatment of heart failure. The results of this study will be included in the Company's presentation today at the BIO Investor Forum in San Francisco, CA.

"The development of a peptide that has natriuretic and renal effects, with relatively little effect on blood pressure, is a potentially important achievement. The results of this trial in healthy volunteers have confirmed some of the hypotheses developed during the pre-clinical studies. We were particularly interested to see a clear, dose dependent increase in cGMP, which suggests the molecule activates the NPR receptors." commented Dr. Barrie Massie, Professor of Medicine, University of California, San Francisco, Chief, Cardiology Section, San Francisco VA Hospital, and member of Nile's scientific advisory board.

Study Design

The Phase 1a study was conducted to investigate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of various doses of CD-NP compared to placebo over a four-hour infusion in 22 healthy volunteers. The study evaluated several pharmacodynamic variables which may translate into safety and efficacy in the heart failure population. Nile measured the effect of CD-NP on systemic blood pressure, urinary flow rate, urinary sodium excretion, serum potassium, renal function and cGMP, a secondary messenger of the target receptor and indicator of in-vivo activity.

Study Results

CD-NP was well tolerated with no serious adverse events and all subjects completed the four-hour infusion of placebo, 10, 17.5 or 25 ng/kg/min of CD-NP.

With respect to clinical and biomarker assessments, CD-NP (placebo, 10, 17.5 and 25 ng/kg/min) increased urine flow rate versus baseline (125%, 53%, 30% and 230% average change, respectively), incre
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014  Diplomat, the nation,s largest independent specialty ... to the Board of Directors on September 15, ... also serve as chair of the Audit Committee. ... accounting, financial, compliance and operating experience in the health ... as chief financial officer, chief operating officer and secretary ...
(Date:9/19/2014)... According to market research ... Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical ... & Geography - Global Trends & Forecast to ... lyophilization market on the basis of various types, ... the market size of each of these segments ...
(Date:9/19/2014)... -- BioSpecifics Technologies Corp. (NASDAQ: BSTC ), a biopharmaceutical ... ® in the U.S. and XIAPEX ® in ... , will present a corporate overview at the 21 st ... The presentation will take place on Friday, September ... Hotel in New York, NY . A ...
Breaking Medicine Technology:David Dreyer Appointed to Diplomat Board of Directors 2Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3BioSpecifics Technologies Corp. to Present at the 21st Annual BioCentury NewsMakers in the Biotech Industry Conference 2
... a quadriplegic triathlete, has been named spokesperson for National ... with disabilities to live active, mobile lifestyles. The goal ... well as the many other transportation solutions that can ... those with disabilities. Savicki is a proud partner along ...
... In the Middle East and North Africa ... MENA region are among the top 10 globally with the ... Bahrain, Egypt, Kuwait, Oman and Saudi Arabia. The region spends ... its total health care expenditure and expenditure averages as high ...
Cached Medicine Technology:69-Time Gold Medalist and Multi-Sport Wheelchair Athlete Named Spokesperson for National Mobility Awareness Month 269-Time Gold Medalist and Multi-Sport Wheelchair Athlete Named Spokesperson for National Mobility Awareness Month 3Meeting of the Region's Top Diabetes Experts in Dubai this March 2
(Date:9/20/2014)... New York, New York (PRWEB) September 20, 2014 ... of power morcellators ( http://www.injurybeacon.com/power-morcellator/ ) in ... notes that yet another insurer has announced plans ... a statement posted on its website last month, ... such procedures effective November 1, 2014. The insurer ...
(Date:9/20/2014)... Recently, Best Cheap Hosting USA (best-cheap-hosting-usa.com), a ... website. The new site provides the latest reviews ... customers. Here, people can find a lot of ... it has recommended some excellent web hosting suppliers ... great web hosting suppliers, InMotion ( http://www.best-cheap-hosting-usa.com/go/InMotion/ ), ...
(Date:9/20/2014)... dentists have advised their patients against drinking coffee and wine. ... that advice and changing his stance after considering two recent ... oral health. “There’s good news and great news,” says Dr. ... protecting against gum disease, and red wine can help fight ... the September 2014 issue of Boston University School of ...
(Date:9/20/2014)... Recently, UWDress.com, an innovative company that provides ... outfits, has launched a special offer for its brand ... popular among worldwide clients. Now, all the company’s new ... on its website. , Additionally, the firm also ... world. Great custom made items can be ordered at ...
(Date:9/20/2014)... New York, NY (PRWEB) September 20, 2014 ... million of their customers may have had their credit card ... late last year, spawning a slew of headline articles ... but those weren’t the only eye opening numbers. , ... numbers were stolen, almost like it’s a way to score ...
Breaking Medicine News(10 mins):Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 2Health News:As Power Morcellator Concerns Grow, Bernstein Liebhard LLP Notes Another Insurer’s Decision to Drop Coverage for Uterine Morcellation 3Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 2Health News:South Charlotte Dentist, Dr. James Wells, is Changing His Advice on Coffee and Wine Drinking 3Health News:Discounted 2014 Prom Dresses Provided By Innovative Company UWDress.com 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 2Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 3Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 4Health News:Don’t Let Data Breach Fatigue Cause Dangerous Cyber Security Complacency 5
... , SALT LAKE CITY, Aug. 4 RIESTER creative from ... National Drug Control Policy (ONDCP) to become a key resource to states ... other approaches combating meth addiction, the End Meth Now campaign inspires hope ... , , "We,ve had the privilege of working ...
... , , COLD SPRING ... the world,s first hand-held, non-contact vein illumination device, announced today that ... to commence European sales of AccuVein,s AV300. , , ... an important step in bringing this beneficial device to healthcare practitioners ...
... lab studies, intermittent calorie restriction led to dramatic decrease ... Periodically cutting calories may lower the risk of developing ... new study published in Cancer Prevention Research . ... tumors were put on different diets: unlimited eating, intermittently ...
... Effort aims to create an international Network of ... co-operative and collaborative approach to combating the problem of health ... Aug. 4 The National Health Care Anti-Fraud Association (NHCAA) ... with two like-minded organizations--the Canadian Health Care Anti-fraud Association (CHCAA) ...
... PALM CITY, Fla., Aug. 4 Connectyx Technologies ... that the Company has formed a partnership with InstantAmber, a ... agreement will enable InstantAmber to offer the MedFlash(TM) product to ... tool that gives parents the ability to keep up to ...
... , , , ... , ALISO VIEJO, Calif., Aug. 4 Valeant Pharmaceuticals International ... 2009. , , "The second quarter once again demonstrated ... and chief executive officer. "We delivered sales and earnings growth at ...
Cached Medicine News:Health News:Office of National Drug Control Policy Taps RIESTER creative for Use in National Anti-Meth Campaign 2Health News:AccuVein Vein Illuminator Receives European CE Mark 2Health News:Periodic Dieting May Cut Breast Cancer Risk 2Health News:The National Health Care Anti-Fraud Association Signs Memorandum of Understanding With Canadian and European Anti-Fraud Organizations 2Health News:The National Health Care Anti-Fraud Association Signs Memorandum of Understanding With Canadian and European Anti-Fraud Organizations 3Health News:Connectyx Partners with InstantAmber, a Leader in Child Safety and Missing Children Awareness 2Health News:Connectyx Partners with InstantAmber, a Leader in Child Safety and Missing Children Awareness 3Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 2Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 3Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 4Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 5Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 6Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 7Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 8Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 9Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 10Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 11Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 12Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 13Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 14Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 15Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 16Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 17Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 18Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 19Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 20Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 21Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 22Health News:Valeant Pharmaceuticals Reports Second Quarter Financial Results 23
Shandon Plastic Slide Boxes...
Shandon Cardboard Slide Folders...
... The new Propaq LT is the ... environment--combining the basic parameters of continuous vital ... new design, making it perfect for just ... place. , Light enough to clip on ...
Exxcel Soft ePTFE vascular graft, designed for exceptional kink resistance and crush resistance, maintains a Soft touch for easier handling during peripheral vascular bypass procedures and vascular a...
Medicine Products: